Jarcy Zee

@jarcyzphd.bsky.social

(she/her) Asst Prof of Biostatistics @UPenn DBEI and @CHOP. Survival, observational, and high-dimensional data methods and kidney disease researcher. Views are my own. www.zeelab.org

@chopresearch.bsky.social Children’s Hospital of Philadelphia Receives Funding to Launch Largest Trial for Children with Chronic Kidney Disease share.google/VDEplEYtZKZD...

Children’s Hospital of Philadelphia Receives Funding to Launch Largest Trial for Children with Chronic Kidney Disease

CHOP announced that PCORI approved a five year award to fund PRESERVE 2.0 – the largest randomized trial on blood pressure management in children with CKD. Children’s Hospital of Philadelphia (CHOP) announced that the Patient-Centered Outcomes Research Institute (PCORI) approved a five‑year funding award to support PRESERVE 2.0, a research project entitled “Alternative Approaches for Managing Blood Pressure in Children With Chronic Kidney Disease.” The study is set to become the largest randomized controlled trial focused on blood pressure management in children with chronic kidney disease (CKD).Hypertension affects roughly half of children with CKD and is a major, modifiable driver of kidney function decline. Loss of kidney function can lead to kidney failure requiring dialysis or transplant. Despite this, high-quality evidence guiding exactly how tightly to control blood pressure and which drugs to use as first-line therapy in most pediatric CKD patients is limited, resulting in wide practice variation and suboptimal blood pressure control for many children. PRESERVE 2.0 aims to fill these evidence gaps.The five-year study, which evolved from the original PCORnet® designated PRESERVE study, will launch in October 2026 and will be led by Co-Principal Investigators, Michelle Denburg, MD, MSCE and Christopher Forrest, MD, PhD at CHOP. The study will enroll 700 children ages 2 to 17 with CKD stages 2 to 4 across 30 U.S. healthcare institutions within PEDSnet and the other six PCORnet® clinical research networks. Participants will be followed for 24 months to compare two blood pressure goals – the usual target and a lower, more intensive target, and to see which first-line blood pressure medicines work better and are safer. Ultimately, PRESERVE 2.0 will answer two high-priority questions for pediatric CKD care: which clinic blood pressure target best protects kidney and heart health, and which medication class should be used first-line to treat hypertension in children with CKD. Michelle Denburg, MD, MSCE “If successful, PRESERVE 2.0 will provide the strongest available evidence about BP targets and first-line antihypertensive choice for most children with CKD,” said Denburg, who is also an attending physician in CHOP’s Division of Nephrology, and co-director of the Penn-CHOP Kidney Innovation Center. “Results are expected to directly inform clinical practice, guideline development, and shared decision-making tools for children with CKD, their families, and clinicians. Findings will be widely disseminated via webinars, infographics, videos, and professional meetings.”Learn more

share.google

regarding Columbia University, I just learned about this (anonymous) account of negotiations of the Hitler regime in the 1930s with Frankfurt University -- Germany's most prestigious university at the time:

Bild

1/9 In recent grant terminations, you might have seen vague justifications about “no longer effectuates agency priorities” (NIH example below). Where did that language come from and what does it mean? BUCKLE UP for a wild ride starting from **8 years ago** 🧵

Excerpt from an NIH grant termination letter that includes, "This award no longer effectuates agency priorities."

Georgetown has put together resources for federal workers who may be facing a transition in jobs. These include various seminars and workshops, as well as tuition scholarships providing a discount on many master's programs and certificates. Please spread the word to anybody who might benefit.

Federal Workforce Transition Resources - Georgetown Graduate School

The Georgetown Graduate School of Arts and Sciences is offering resources to assist in federal workforce transitions. Check out our career seminars to learn more.

grad.georgetown.edu

Continuing our Women’s History Month series, we celebrate Dr. Kay See Tan, Associate Attending Biostatistician at Memorial Sloan Kettering Cancer Center, for her efforts in diversifying and training the next generation of biostatisticians. #ENAR #WomensHistoryMonth

BildBild

What’s the difference between a right-censored covariate and a missing covariate? Can they be treated the same? If you’re attending #2025ENAR, join my presentation! I’ll answer these questions + introduce robust and efficient estimators for regression analysis with a right-censored covariate!

Bild

Happy Women’s History Month! Today, we’re featuring HarLeigh Haynie, a biostatistician at Wake Forest School of Medicine. Her favorite R package is Janitor, and she shares a stats joke: Why did the statistician break up with the mathematician? They couldn’t find a common variable! #ENAR

Bild